FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2148338637> ?p ?o ?g. }

• W2148338637 endingPage "528" @default.
• W2148338637 startingPage "522" @default.
• W2148338637 abstract "Two randomized phase III trials of first-line chemotherapy for advanced gastric cancer (JCOG9205 and JCOG9912) conducted by the Japan Clinical Oncology Group used 5-fluorouracil continuous infusion (5-FUci) as the control arm. New active agents (e.g., S-1, irinotecan, and taxanes) were introduced as second-line chemotherapy in the late 1990s after JCOG9205. This combined analysis evaluated whether patients in the 5-FUci arm of JCOG9912 exhibited better survival after adjusting for baseline factors and also investigated the cause of survival prolongation. The subjects were patients assigned to the 5-FUci arms who met the eligibility criteria of both JCOG9205 and JCOG9912. Overall survival (OS), time to treatment failure (TTF), and survival after treatment failure in the first-line chemotherapy (OS-TTF) were compared after adjusting baseline characteristics using the Cox proportional hazard model. Second-line chemotherapy details were also reviewed. The combined analysis included 89 and 230 patients in JCOG9205 and JCOG9912, respectively. After adjusting baseline characteristics, TTF was similar between groups (HR 0.95; 95 % CI, 0.73–1.26). However, both OS (HR, 0.74; 95 % CI, 0.56–0.99) and OS-TTF (HR, 0.76; 95 % CI, 0.57–1.01) were longer in JCOG9912. More patients in JCOG9912 received second-line chemotherapy (83 vs. 52 %) with new drugs (77 vs. 10 %) than in JCOG9205. OS-TTF was substantially prolonged in patients who received second-line chemotherapy (HR, 0.66; 95 % CI, 0.46–0.95). OS and OS-TTF were longer in JCOG9912 than JCOG9205. Second-line chemotherapy with new drugs is a potential reason for the observed prolongation of survival." @default.
• W2148338637 created "2016-06-24" @default.
• W2148338637 creator A5005598571 @default.
• W2148338637 creator A5010090426 @default.
• W2148338637 creator A5023430800 @default.
• W2148338637 creator A5024904484 @default.
• W2148338637 creator A5026907664 @default.
• W2148338637 creator A5034287641 @default.
• W2148338637 creator A5039783762 @default.
• W2148338637 creator A5056915467 @default.
• W2148338637 creator A5082832235 @default.
• W2148338637 date "2013-10-26" @default.
• W2148338637 modified "2023-10-16" @default.
• W2148338637 title "Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology Group Trials JCOG9205 and JCOG9912" @default.
• W2148338637 cites W1944693814 @default.
• W2148338637 cites W1976651872 @default.
• W2148338637 cites W1981324047 @default.
• W2148338637 cites W1992408996 @default.
• W2148338637 cites W2013537137 @default.
• W2148338637 cites W2019814348 @default.
• W2148338637 cites W2068225833 @default.
• W2148338637 cites W2083240168 @default.
• W2148338637 cites W2104631255 @default.
• W2148338637 cites W2114734455 @default.
• W2148338637 cites W2130522735 @default.
• W2148338637 cites W2155167083 @default.
• W2148338637 cites W2160161167 @default.
• W2148338637 cites W2164011084 @default.
• W2148338637 cites W2164411042 @default.
• W2148338637 cites W2331031707 @default.
• W2148338637 cites W2338576041 @default.
• W2148338637 cites W4210975948 @default.
• W2148338637 cites W4231021828 @default.
• W2148338637 doi "https://doi.org/10.1007/s10120-013-0309-z" @default.
• W2148338637 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24162387" @default.
• W2148338637 hasPublicationYear "2013" @default.
• W2148338637 type Work @default.
• W2148338637 sameAs 2148338637 @default.
• W2148338637 citedByCount "21" @default.
• W2148338637 countsByYear W21483386372013 @default.
• W2148338637 countsByYear W21483386372015 @default.
• W2148338637 countsByYear W21483386372016 @default.
• W2148338637 countsByYear W21483386372017 @default.
• W2148338637 countsByYear W21483386372018 @default.
• W2148338637 countsByYear W21483386372019 @default.
• W2148338637 countsByYear W21483386372020 @default.
• W2148338637 countsByYear W21483386372021 @default.
• W2148338637 countsByYear W21483386372022 @default.
• W2148338637 crossrefType "journal-article" @default.
• W2148338637 hasAuthorship W2148338637A5005598571 @default.
• W2148338637 hasAuthorship W2148338637A5010090426 @default.
• W2148338637 hasAuthorship W2148338637A5023430800 @default.
• W2148338637 hasAuthorship W2148338637A5024904484 @default.
• W2148338637 hasAuthorship W2148338637A5026907664 @default.
• W2148338637 hasAuthorship W2148338637A5034287641 @default.
• W2148338637 hasAuthorship W2148338637A5039783762 @default.
• W2148338637 hasAuthorship W2148338637A5056915467 @default.
• W2148338637 hasAuthorship W2148338637A5082832235 @default.
• W2148338637 hasBestOaLocation W21483386371 @default.
• W2148338637 hasConcept C10515644 @default.
• W2148338637 hasConcept C121608353 @default.
• W2148338637 hasConcept C126322002 @default.
• W2148338637 hasConcept C141071460 @default.
• W2148338637 hasConcept C143998085 @default.
• W2148338637 hasConcept C207103383 @default.
• W2148338637 hasConcept C2776694085 @default.
• W2148338637 hasConcept C2780140570 @default.
• W2148338637 hasConcept C2780259306 @default.
• W2148338637 hasConcept C44249647 @default.
• W2148338637 hasConcept C526805850 @default.
• W2148338637 hasConcept C535046627 @default.
• W2148338637 hasConcept C71924100 @default.
• W2148338637 hasConcept C90924648 @default.
• W2148338637 hasConceptScore W2148338637C10515644 @default.
• W2148338637 hasConceptScore W2148338637C121608353 @default.
• W2148338637 hasConceptScore W2148338637C126322002 @default.
• W2148338637 hasConceptScore W2148338637C141071460 @default.
• W2148338637 hasConceptScore W2148338637C143998085 @default.
• W2148338637 hasConceptScore W2148338637C207103383 @default.
• W2148338637 hasConceptScore W2148338637C2776694085 @default.
• W2148338637 hasConceptScore W2148338637C2780140570 @default.
• W2148338637 hasConceptScore W2148338637C2780259306 @default.
• W2148338637 hasConceptScore W2148338637C44249647 @default.
• W2148338637 hasConceptScore W2148338637C526805850 @default.
• W2148338637 hasConceptScore W2148338637C535046627 @default.
• W2148338637 hasConceptScore W2148338637C71924100 @default.
• W2148338637 hasConceptScore W2148338637C90924648 @default.
• W2148338637 hasIssue "3" @default.
• W2148338637 hasLocation W21483386371 @default.
• W2148338637 hasLocation W21483386372 @default.
• W2148338637 hasOpenAccess W2148338637 @default.
• W2148338637 hasPrimaryLocation W21483386371 @default.
• W2148338637 hasRelatedWork W1964795883 @default.
• W2148338637 hasRelatedWork W2013809648 @default.
• W2148338637 hasRelatedWork W2020973556 @default.
• W2148338637 hasRelatedWork W2040350626 @default.
• W2148338637 hasRelatedWork W2056185445 @default.
• W2148338637 hasRelatedWork W2417717847 @default.

• next